Welcome to our dedicated page for BlossomHill Therapeutics SEC filings (Ticker: BLSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BlossomHill Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BlossomHill Therapeutics's regulatory disclosures and financial reporting.
BlossomHill Therapeutics, Inc. (BLSM) reported the initial insider holdings of its Chief Financial Officer, Jason A. Keyes, on a Form 3. He holds an employee stock option covering 175,417 shares of common stock at an exercise price of $6.28 per share, expiring on May 5, 2035. The option is noted as immediately exercisable and is held as a direct ownership position.